Carl Berg

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 28, 2023
Health, Mental Health, Biometrics, Anxiety, Biotechnology, VC, Therapy, Clostridium, Cancer, University, Ernst & Young, Immune system, Family, Depression, Accounting, Clostridioides difficile infection, Carl Berg, BDO USA, LLP, Drug discovery, BS, CNS, CPA, Employment, University of Massachusetts Chan Medical School, RSU, CFO, HR, VSI, Central nervous system disease, Addiction, Pharmaceutical industry, Management, Nursing, Finance, Patient, Enver Pasha, Vedanta

Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies.

Key Points: 
  • Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies.
  • “We are extremely pleased to add Kevin to the leadership team at Enveric Biosciences.
  • “I am excited to join the team at Enveric at such a crucial time for the Company,” said Mr. Coveney.
  • The grant was approved by the board of directors of the Company and will be made as an inducement material to Mr. Coveney entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer

Retrieved on: 
Tuesday, January 10, 2023
Disease, Neurodegeneration, University, The Institute, Therapy, Cedars-Sinai Medical Center, Biotechnology, MD, Radiation, Patient, George Washington University, Institut Gustave Roussy, Research, Cancer, ASTRO, CMO, Carl Berg, Chicago (franchise), Pharmaceutical industry, NK

Song, MD as Chief Executive Officer (CEO) and Vice Chairman of the Board of Directors, effective January 10, 2023.

Key Points: 
  • Song, MD as Chief Executive Officer (CEO) and Vice Chairman of the Board of Directors, effective January 10, 2023.
  • “We are thrilled to welcome Paul as our new CEO and the experience, vision and leadership Paul brings to NKGen Biotech,” said Sangwoo Park, Founder and Chairman of NKGen Biotech.
  • “Paul will play a critical role in leading our company’s corporate strategy and the advancement of our potentially life-changing clinical portfolio in oncology and neurodegenerative disease.
  • Song, MD, CEO of NKGen Biotech.

DataShapes Receives $5 Million In Funding

Retrieved on: 
Tuesday, March 1, 2022
Health, SAN, Software as a service, Knowledge, Intelligence, Industry, Carl Berg, Solution, CEO, IDC, Metadata, Mobile phone

DataShapes uses its patented Vector Learning technology to create SaaS solutions that capture and automate industry expertise by transforming unstructured edge-device data into immediately actionable information.

Key Points: 
  • DataShapes uses its patented Vector Learning technology to create SaaS solutions that capture and automate industry expertise by transforming unstructured edge-device data into immediately actionable information.
  • "Developed over five years at a cost of $20 million, DataShapes is now applying its Vector Learning to unlock vast amounts of edge data," said Carl Berg, founder of Berg Venture Capital and Berg Health.
  • "The edge is an ocean of data, but there's hardly a drop to drink," said Jon Myers, founder and CEO of DataShapes.
  • By transforming data at its source, DataShapes' solutions dramatically reduce processing costs, data size, and the latency between sensing and acting.

Memgen Appoints Kevin M. Coveney as Chief Financial Officer

Retrieved on: 
Wednesday, November 17, 2021
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Cancer, BDO USA, LLP, Clinical trial, EY, Immune system, CPA, Information technology, Artificial intelligence, Multimedia, Research, Biotechnology, Carl Berg, CD40, Toxicity, Food, Patient, Pharmaceutical industry

Memgen, Inc. , a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.

Key Points: 
  • Memgen, Inc. , a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20211117005439/en/
    Kevin M. Coveney is Memgen's new chief financial officer.
  • (Photo: Business Wire)
    We are delighted to have Kevin join the Memgen leadership team, said Gregory Brown, M.D., Chief Executive Officer of Memgen.
  • Prior to Memgen, Mr. Coveney was chief financial officer of Q-State Biosciences, a preclinical biotechnology company.